Non-Cystic Fibrosis Bronchiectasis Study
A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 Multi-Phage Therapeutic in Subjects with Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas aeruginosa Infection
Sex at Birth: All
Healthy Participants: No
Condition: Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa
Location: University Hospitals Medical Centers
Learn More About This Research Study
For more information, please contact study coordinator Briana Jackson at 216-983-0891 or by completing the form below.
Study Purpose
The main purpose of this research study is to learn how well the investigational study drug works; how long the study drug stays and works in the airway, and how safe the study drug is when taken alone (or in combination with inhaled antibiotics) compared with placebo and inhaled antibiotics alone. A placebo is an inactive material that looks like the study drug but does not have any active study drug. Researchers use a placebo to see if the study drug works better or is safer than taking nothing.
Who Can Participate
Participants 18 years of age or older with non-cystic fibrosis bronchiectasis or chronic pulmonary pseudomonoas aeruginosa may be eligible of this research study.
- STUDY20231258